Chondrosarcomas are a type of primary malignant
bone cancer, with a potent capacity for local invasion and distant
metastasis.
Brain-derived neurotrophic factor (
BDNF) is commonly upregulated during neurogenesis. The aim of the present study was to examine the mechanism involved in
BDNF-mediated
vascular endothelial growth factor (
VEGF) expression and angiogenesis in human
chondrosarcoma cells. Here, we knocked down
BDNF expression in
chondrosarcoma cells and assessed their capacity to control
VEGF expression and angiogenesis in vitro and in vivo. We found knockdown of
BDNF decreased
VEGF expression and abolished
chondrosarcoma conditional medium-mediated angiogenesis in vitro as well as
angiogenesis effects in vivo in the chick chorioallantoic membrane and
Matrigel plug nude mouse models. In addition, in the xenograft
tumor angiogenesis model, the knockdown of
BDNF significantly reduced
tumor growth and
tumor-associated angiogenesis.
BDNF increased
VEGF expression and angiogenesis through the
TrkB receptor, PLCγ, PKCα, and the HIF-1α signaling pathway. Finally, we analyzed samples from
chondrosarcoma patients by immunohistochemical staining. The expression of
BDNF and
VEGF protein in 56
chondrosarcoma patients was significantly higher than in normal cartilage. In addition, the high level of
BDNF expression correlated strongly with
VEGF expression and
tumor stage. Taken together, our results indicate that
BDNF increases
VEGF expression and enhances angiogenesis through a signal transduction pathway that involves the
TrkB receptor, PLCγ, PKCα, and the HIF-1α. Therefore,
BDNF may represent a novel target for anti-angiogenic
therapy for human
chondrosarcoma.